LLY · News · 20260824N
Product Launch - Foundayo
ELI LILLY & Co · 2026-08-24 · Importance 31 · Surprise 42
Eli Lilly launched its once-daily oral weight-loss and type 2 diabetes pill Foundayo (orforglipron) in the United Kingdom, its first European market. The product is available through private prescriptions for adults with a body-mass index of at least 30, or 27 to 30 with a weight-related health condition. Foundayo is priced below Lilly’s Mounjaro injection, while Lilly is discussing potential NHS availability with NICE, broadening its prospective access beyond private-pay channels.
Key facts
- Foundayo was approved for patients with a body mass index of at least 30, or between 27 and 30 in the event of at least one weight-related health condition. source